Miranda Schmalfuhs

Arda Ural discusses the possible impact on how companies plan for growth based on the impact of the tariffs.

Arda Ural discusses the different ways that companies may change the ways they allocate resources in the current geopolitical climate.

Lynlee Brown, partner at EY, discusses the impacts that the tariffs have across various regions.

Arda Ural explains how the tariffs will impact profit margins and potentially cause drug shortages.

Lynlee Brown discusses the decisions that companies must make to adjust to the tariffs while also ensuring the ongoing innovation continues.

Ted Sweetser discusses turning information into usable datasets and pulling insights from them.

Ted Sweetser discusses how more accurate datasets are solving problems related to getting communities access to better healthcare.

Ted Sweetser discusses how the technology is providing greater insight into how marketing materials are being viewed.

Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, explores the potential synergy between myopathies and obesity in terms of patient populations and underlying biological mechanisms.

Ted Sweetser discusses how the technology is expanding the amount of content that can be created.

Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, discusses getting JUV-161 into Phase I trials this year.

Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, explains how Juvena plans to differentiate JUV-112 from other obesity therapeutics targeting adipose tissue.

Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, discusses how the "multiple confidential discussions" mentioned in their pipeline regarding their obesity (muscle target) program may impact the development timeline or potential partnerships for the program.

LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.

The latest news for pharma industry insiders.

Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, discusses Juvena’s "pipeline in a product" JUV-161 and plans to broaden into other disease indications.

The latest news for pharma industry insiders.

LaShell Robinson, head of global feasibility and trial equity at Takeda, discusses how Takeda will ensure that diversity and inclusion remain a priority in its clinical trials moving forward.

The latest news for pharma industry insiders.

The latest news for pharma industry insiders.

Amy Hessels, Bayer‘s vice president of marketing, talks about how to engage younger demographics and how the Your Decision campaign contributes to broader conversations about women's reproductive autonomy and healthcare access.

LaShell Robinson, head of global feasibility and trial equity at Takeda, identifies some of the key barriers in achieving representative clinical trials for psoriasis, and how they are overcoming them.

Amy Hessels, vice president of marketing, Bayer, discusses how its Your Decision campaign tackles misinformation about reproductive health by providing the information to empower women to discuss options with healthcare providers.

The latest news for pharma industry insiders.

LaShell Robinson, head of global feasibility and trial equity at Takeda, talks about Takeda's aims to expand its efforts globally by adapting strategies to regional needs.

LaShell Robinson, head of global feasibility and trial equity at Takeda, discusses strategies to address underrepresentation in clinical trials, particularly in phase III psoriasis trials.

The latest news for pharma industry insiders.

The latest news for pharma industry insiders.

Marcel Botha, CEO of 10XBeta, identifies the most significant technological innovations in medical device manufacturing that will be crucial for future pandemic preparedness and supply chain stability.

Matthew Yelovich, partner at Cleary Gottlieb, discusses his transition in late-2024 from working as a federal prosecutor to a role at Cleary Gottlieb, as well as how he sees the intersection of technology and law evolving in the Bay Area.